Gemcitabine

Catalog No.S1714

Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Price Stock Quantity  
USD 130 In stock
USD 97 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gemcitabine  Chemical Structure

Gemcitabine Chemical Structure
Molecular Weight: 263.2

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Gemcitabine is available in the following compound libraries:

Product Information

  • Compare DNA/RNA Synthesis Inhibitors
    Compare DNA/RNA Synthesis Products
  • Research Area

Product Description

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXm2TlhjUUN3ME2wMlAxODR3ODDuUS=>M{nxOXNCVkeHUh?=
ES4Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTye21uUUN3ME2wMlAxODZ3MzDuUS=>NVLxfINtW0GQR1XS
ACHNMmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zNcWlEPTB;MD6wNFA5QDdibl2=NVjsfG5{W0GQR1XS
KYSE-510NHjmT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DUc2lEPTB;MD6wNFA6PzVibl2=NUnGeok5W0GQR1XS
EW-7NIH3OnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\zTWM2OD1yLkCwNlU5KG6PNGPJOYtUSU6JRWK=
BFTC-905MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTKc5FoUUN3ME2wMlAxPTF3IH7NNFLDbnZUSU6JRWK=
KE-37M3jp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTBwMEC1OlEhdk1?MlztV2FPT0WU
SBC-5M3HRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfHcFhKSzVyPUCuNFA2PyCwTR?=NHvkZ4lUSU6JRWK=
NKM-1NUnSVGg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPHTWM2OD1yLkCwO|A6KG6PNHPMeIJUSU6JRWK=
RH-1NGTZZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{j2N2lEPTB;MD6wNFcyQCCwTR?=M4\vOXNCVkeHUh?=
ALL-PONG\ic4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DJW2lEPTB;MD6wNFg{KG6PNHH0UoxUSU6JRWK=
QIMR-WILMmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Lv[mlEPTB;MD6wNFg6PCCwTR?=NX7NXnpkW0GQR1XS
A375NHW0bXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fkOGlEPTB;MD6wNFk6PSCwTR?=M3XTPHNCVkeHUh?=
SIG-M5M3KzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HQPGlEPTB;MD6wNVA1KG6PMmf0V2FPT0WU
KGNNUOyWoxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1q3XWlEPTB;MD6wNVA5KG6PM2npU3NCVkeHUh?=
EW-13NFfhS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\M[ldrUUN3ME2wMlAyOTJibl2=NGr4UpNUSU6JRWK=
NCI-SNU-1NGfzTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTBwMEG2JI5OM1POenNCVkeHUh?=
PSN1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTBwMEG2OUBvVQ>?NX;jOHZ[W0GQR1XS
HUTU-80NF\3N3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIS0VoNKSzVyPUCuNFE3PiCwTR?=NVHHRms4W0GQR1XS
EW-16M3n5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnf0TWM2OD1yLkCyN{BvVQ>?NIDLd2xUSU6JRWK=
786-0M2K5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTBwMEKzJI5ONWnCOIZNW0GQR1XS
ES1NYPo[JJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPjZVBKSzVyPUCuNFI3QCCwTR?=NGSzZYFUSU6JRWK=
RKOM3H6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwMEK3PUBvVQ>?MlPrV2FPT0WU
ESS-1M2LVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzvTohKSzVyPUCuNFI5PiCwTR?=NYDXbII4W0GQR1XS
SK-UT-1NGfxUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PaUmlEPTB;MD6wNlk4KG6PM4WxU3NCVkeHUh?=
LB2241-RCCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHlTWM2OD1yLkCzNVghdk1?MYnTRW5ITVJ?
CHL-1Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDmbWtKSzVyPUCuNFMzPCCwTR?=M4rQdnNCVkeHUh?=
SW1783MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXf2[JI4UUN3ME2wMlA{OzZibl2=M1e3d3NCVkeHUh?=
MEL-JUSOM4f0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTBwMEO5NUBvVQ>?MmDRV2FPT0WU
HT-29MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTBwMESxN{BvVQ>?M1zhRXNCVkeHUh?=
SNG-MNWPERZdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LvXGlEPTB;MD6wOFI2KG6PNF\JSXNUSU6JRWK=
TE-15MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTBwMES2OEBvVQ>?MWfTRW5ITVJ?
HOSMlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzKZWVKSzVyPUCuNFQ5KG6PM2[1XnNCVkeHUh?=
BB65-RCCMnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTScY9KSzVyPUCuNFUyOiCwTR?=NELiOJVUSU6JRWK=
HCE-4MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHpe2dKSzVyPUCuNFUzQCCwTR?=NYLrWGJQW0GQR1XS
MHH-ES-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Ls[WlEPTB;MD6wOVMyKG6PM4fZdHNCVkeHUh?=
RPMI-7951NW\T[2p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTBwMEW0NUBvVQ>?MkXYV2FPT0WU
IST-SL2NUHCT4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XZZWlEPTB;MD6wOVg1KG6PNFrWe25USU6JRWK=
CMKMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwMEW4OkBvVQ>?NVzwUVRxW0GQR1XS
GR-STMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmftTWM2OD1yLkC1PVUhdk1?MlK2V2FPT0WU
NALM-6MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjoTWM2OD1yLkC2NlIhdk1?Ml\pV2FPT0WU
RPMI-6666NXjLbJVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PvUmlEPTB;MD6wOlUzKG6PMm\SV2FPT0WU
LC-2-adM3TibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUThV2NNUUN3ME2wMlA3PTNibl2=NFj5enlUSU6JRWK=
ARH-77NIe1UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnBW|drUUN3ME2wMlA4OTFibl2=M3KzS3NCVkeHUh?=
IST-MEL1MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnD[3dKSzVyPUCuNFczPiCwTR?=NHn1b4NUSU6JRWK=
SW1710NWK2bnhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnNU5VKSzVyPUCuNFc2OSCwTR?=NXnV[mxSW0GQR1XS
DELM{TvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LpfWlEPTB;MD6wPFg4KG6PMknWV2FPT0WU
AGSMlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17afWlEPTB;MD6wPVAzKG6PNWPkXWE2W0GQR1XS
NCI-H2122NYfVfm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTBwMEm0OkBvVQ>?NIK1cpdUSU6JRWK=
HSC-4MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XoVmlEPTB;MD6xNFIhdk1?NUDsfoV[W0GQR1XS
AM-38MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfuS2NKSzVyPUCuNVIyKG6PMXHTRW5ITVJ?
769-PNILCRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTnSXlKSzVyPUCuNVI{KG6PMorIV2FPT0WU
RT-112NVPXOoE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HJdGlEPTB;MD6xNlchdk1?M{DCWXNCVkeHUh?=
MCF7NWLBW|V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTBwMUO2JI5ONYrzNJJOW0GQR1XS
IGROV-1M1rqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTBwMUS1JI5ONXrMV4JFW0GQR1XS
OCI-AML2Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\OeIFqUUN3ME2wMlE1PyCwTR?=NEPyUHVUSU6JRWK=
NCI-H1299MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml[wTWM2OD1yLkG1O{BvVQ>?NW\EPIRiW0GQR1XS
A431MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTBwMUizJI5OMUTTRW5ITVJ?
SW982M2TqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnDRplKSzVyPUCuNlE{KG6PMWXTRW5ITVJ?
BB30-HNCNEL2coVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn[xTWM2OD1yLkKzNUBvVQ>?MoDaV2FPT0WU
ACNNFvPcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTmNZZKSzVyPUCuNlQ1KG6PMUnTRW5ITVJ?
647-VM3HRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHITWlqUUN3ME2wMlI1QCCwTR?=MV7TRW5ITVJ?
SK-PN-DWNULMW5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYi0UHJIUUN3ME2wMlI3PiCwTR?=NWno[m5LW0GQR1XS
LCLC-97TM1NVrNXFdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjTdpFjUUN3ME2wMlI3PyCwTR?=NXy3Z3dqW0GQR1XS
LB1047-RCCNXPT[WxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPsOJJKSzVyPUCuNlY6KG6PNWLa[HBEW0GQR1XS
A2780MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\mTWpKSzVyPUCuNlchdk1?NVjKVnZPW0GQR1XS
C-33-AM4r0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTBwMkezJI5ONU[2UldUW0GQR1XS
NCI-H2228NHPHbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGD6Z2lKSzVyPUCuN|E1KG6PMlu4V2FPT0WU
TE-5M4nnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfTUY1KSzVyPUCuN|E3KG6PNX3jWlNVW0GQR1XS
HC-1NWTSe29TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{P6W2lEPTB;MD6zNlchdk1?MVvTRW5ITVJ?
SK-MES-1NXjrPIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnywTWM2OD1yLkOyPEBvVQ>?M3\yRXNCVkeHUh?=
NCI-H1355Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDGTWM2OD1yLkO4NUBvVQ>?NELPUHFUSU6JRWK=
YKG-1NFn0XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTMSpFKSzVyPUCuOFE6KG6PNUj0emRzW0GQR1XS
RS4-11MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDFTWM2OD1yLkSzN{BvVQ>?MmLTV2FPT0WU
DaoyNVvtXpp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;QemlEPTB;MD60OVYhdk1?M1\4e3NCVkeHUh?=
A3-KAWM4D5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2[3fmlEPTB;MD61OVEhdk1?M33kVHNCVkeHUh?=
SK-MEL-30MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3ntWGlEPTB;MD61OVQhdk1?MXTTRW5ITVJ?
U031M2\Gc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPwTWM2OD1yLkW2OUBvVQ>?M{S2fHNCVkeHUh?=
SK-LMS-1MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGriPFZKSzVyPUCuOVc5KG6PM4DueXNCVkeHUh?=
ES6NH\VNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3KxZWlEPTB;MD61PFYhdk1?MWfTRW5ITVJ?
EoL-1-cellM2rERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPaVnBQUUN3ME2wMlYyPiCwTR?=M33DS3NCVkeHUh?=
NCI-H2009MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1r0RmlEPTB;MD62NVkhdk1?M4m0WnNCVkeHUh?=
A4-FukMlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\NO21KSzVyPUCuOlI3KG6PM2XMVHNCVkeHUh?=
KYSE-270NV\sPY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTBwNkO0JI5ONEjDe4NUSU6JRWK=
SK-LU-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkH4TWM2OD1yLk[1OUBvVQ>?NUfoXnl4W0GQR1XS
SW872NInlXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4T3T2lEPTB;MD63OlUhdk1?MUjTRW5ITVJ?
ES8NIK5dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTwfpRKSzVyPUCuO|ghdk1?M2rITnNCVkeHUh?=
G-402M4WwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzCRVFpUUN3ME2wMlc5PCCwTR?=MWnTRW5ITVJ?
ATN-1NHm4NnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrSTWM2OD1yLkiwO{BvVQ>?MWTTRW5ITVJ?
DoTc2-4510M{C1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTBwOUCxJI5OMmjhV2FPT0WU
MES-SANVfMRlhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHvSVhvUUN3ME2wMlkxPSCwTR?=MYfTRW5ITVJ?
SF268Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLhU4tKSzVyPUCuPVI4KG6PM{TyOnNCVkeHUh?=
SF539MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2n4b2lEPTB;MT6wNkBvVQ>?NH;aUGhUSU6JRWK=
NB69MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nkOGlEPTB;MT6wOUBvVQ>?NETy[pRUSU6JRWK=
8505CNYXiO2FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPMVppKSzVyPUGuNFYhdk1?MXzTRW5ITVJ?
CAL-12TNF3IbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHCPII5UUN3ME2xMlA5KG6PNVfkZYhMW0GQR1XS
BHYMmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rjcGlEPTB;MT6xOEBvVQ>?MV\TRW5ITVJ?
LB647-SCLCM1vE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTFwMUigcm0>NHjVeFJUSU6JRWK=
CAL-62NH\EfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkKwTWM2OD1zLkKyJI5ONWPqTFdyW0GQR1XS
MEG-01M1nPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rOVGlEPTB;MT6yO{BvVQ>?M1fmPXNCVkeHUh?=
MG-63NH3xVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTFwM{Ogcm0>NYHaeXRCW0GQR1XS
SW620NIfoZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGSxdIlKSzVyPUGuN|Uhdk1?Mnf2V2FPT0WU
A388M1;MR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTFwM{[gcm0>NH\LWJdUSU6JRWK=
BCPAPNITYWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXyeZBjUUN3ME2xMlQ2KG6PNUnMeJZ[W0GQR1XS
P30-OHKMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYC4foFjUUN3ME2xMlQ3KG6PNEf6WGNUSU6JRWK=
Ca9-22MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1:xR2lEPTB;MT61OEBvVQ>?MkfjV2FPT0WU
VMRC-RCZNXjPcFJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTFwNUSgcm0>M3\LOnNCVkeHUh?=
LOXIMVINFHRWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnz0TWM2OD1zLk[gcm0>MmrzV2FPT0WU
L-540M2DrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGO2fo5KSzVyPUGuOkBvVQ>?NUfaNWNZW0GQR1XS
NTERA-S-cl-D1NWH3WYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfhTWM2OD1zLk[0JI5OM{fLRXNCVkeHUh?=
MFH-inoNYPoZ3lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTFwNk[gcm0>MlnLV2FPT0WU
Calu-6MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjWTWM2OD1zLkezJI5OMXHTRW5ITVJ?
HELNHzacG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoCxTWM2OD1zLke5JI5ONXnXSY01W0GQR1XS
CAL-33MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PrXWlEPTB;MT64PUBvVQ>?NEXmcWRUSU6JRWK=
HSC-3NX\GbIVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnNNZRKSzVyPUGuPVEhdk1?NHPXbYVUSU6JRWK=
KU812NWPoPFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvtcnpKSzVyPUGuPVEhdk1?MmK5V2FPT0WU
EB2NX7Ye401T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjsdVdKSzVyPUKuNFEhdk1?MVnTRW5ITVJ?
SRM3nNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrFW3hCUUN3ME2yMlEzKG6PM1zZUnNCVkeHUh?=
NCI-H2087M{TlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\uZZpKSzVyPUKuNVQhdk1?M3XDcHNCVkeHUh?=
H4NWnq[HZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTCTWM2OD1{LkG4JI5OMXXTRW5ITVJ?
EW-1NVXhNWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jVcGlEPTB;Mj6yNkBvVQ>?MXPTRW5ITVJ?
MC-IXCNID4T4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXUO2puUUN3ME2yMlI3KG6PNFTG[YdUSU6JRWK=
NCI-H727NGK1VXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI[5bYRKSzVyPUKuOVEhdk1?MkXQV2FPT0WU
MRK-nu-1M3zZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLBVXNKSzVyPUKuOVchdk1?MkPOV2FPT0WU
COLO-668NGi4S5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3mycmlEPTB;Mj62OkBvVQ>?NFfqU|ZUSU6JRWK=
CGTH-W-1MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTJwN{Kgcm0>MYPTRW5ITVJ?
CHP-212NXrWSItIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJwN{Wgcm0>NIrFeYRUSU6JRWK=
GI-1MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vUdGlEPTB;Mj63OkBvVQ>?NIC4bW5USU6JRWK=
HCC1806NVHWdpMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTJwOUGgcm0>M4e5SHNCVkeHUh?=
HLEMn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3VTWM2OD1|IH7NM{LHeXNCVkeHUh?=
HSC-2MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTNwMEOgcm0>NVmxcXplW0GQR1XS
DMS-273MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYD5PZA3UUN3ME2zMlA4KG6PMV\TRW5ITVJ?
DU-4475NIOxS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\6TJJKSzVyPUOuNVQhdk1?MXzTRW5ITVJ?
LXF-289MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDOTWM2OD1|LkOxJI5OM2G5NnNCVkeHUh?=
PANC-03-27MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTNwNUGgcm0>MonIV2FPT0WU
GAMGMkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPBdlc3UUN3ME2zMlc1KG6PMm\6V2FPT0WU
NCI-H522MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLuTWM2OD12LkO0JI5OMl3hV2FPT0WU
SW626NUDpUpZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjOe2xJUUN3ME20MlQ3KG6PMnXTV2FPT0WU
HT-144NVXWepV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LLSmlEPTB;ND65NkBvVQ>?NIjDc5FUSU6JRWK=
MEL-HOMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmH0TWM2OD13LkG2JI5ONVzLe29LW0GQR1XS
BE-13M3r2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\mWXJSUUN3ME21MlIyKG6PMY\TRW5ITVJ?
VA-ES-BJM1;Rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTVwMk[gcm0>M2LtNHNCVkeHUh?=
NCI-H441MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3X5[mlEPTB;NT62JI5OMYrTRW5ITVJ?
KP-4NVnCeVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTVwNkGgcm0>NXP6SXBGW0GQR1XS
LoVoNVXH[pFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjwcHRKSzVyPUWuO|Ehdk1?M4HSZ3NCVkeHUh?=
HT-1080NVrMZ3Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nxTmlEPTB;NT64N{BvVQ>?NWD5SHZHW0GQR1XS
GB-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTVwOESgcm0>NHO3XWlUSU6JRWK=
IA-LMMkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTVwOUGgcm0>MV\TRW5ITVJ?
8-MG-BANYjQZoYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTVwOUOgcm0>MVTTRW5ITVJ?
SK-HEP-1M3m1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HKRWlEPTB;Nj6xOEBvVQ>?M3fobXNCVkeHUh?=
697NVPzfZBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojFTWM2OD14LkK1JI5OMWfTRW5ITVJ?
KYSE-450NVLjc4hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTZwM{Kgcm0>NWLOeZdEW0GQR1XS
HCC2998MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTZwM{Sgcm0>NIXQ[mVUSU6JRWK=
HD-MY-ZMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkH2TWM2OD14Lk[4JI5OM4TS[HNCVkeHUh?=
OS-RC-2MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTRTWM2OD14Lk[4JI5ONHq1dHBUSU6JRWK=
SF126M{jpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2O3d2lEPTB;Nz6wOUBvVQ>?NGLVb3hUSU6JRWK=
Ca-SkiNXG3SJlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PyTmlEPTB;Nz6wPUBvVQ>?NY[zcG04W0GQR1XS
NCI-H358NX;2N2N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPuTWM2OD15LkG2JI5ONEi3cpJUSU6JRWK=
J82MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTdwNEGgcm0>MUPTRW5ITVJ?
NCI-H2342Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7OTWM2OD15Lk[zJI5ONYDjUIxLW0GQR1XS
OVCAR-8NHvLeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDwTWM2OD15Lkmgcm0>MofwV2FPT0WU
TE-8NIW5b2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfhNm9XUUN3ME24JI5ONWq1W3NZW0GQR1XS
ETK-1M1n0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{frZ2lEPTB;OD6wPEBvVQ>?NFLJTlNUSU6JRWK=
HAL-01NFyyc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjBTWM2OD16LkKgcm0>NFvpUnlUSU6JRWK=
KYSE-150M3TyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnsPFd{UUN3ME24MlQ4KG6PMUnTRW5ITVJ?
NCI-H810NIPv[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HQVGlEPTB;OD61OkBvVQ>?MY\TRW5ITVJ?
ONS-76NUe4[m5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3Tue2lEPTB;OD62PEBvVQ>?MlHLV2FPT0WU
NMC-G1NYf3Ro5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInoXYZKSzVyPUiuO|Yhdk1?M32wTXNCVkeHUh?=
C3ANYrTXohYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\VVlRKSzVyPUiuPFQhdk1?MUDTRW5ITVJ?
PA-1NEHq[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRThwOUmgcm0>MlvzV2FPT0WU
SH-4MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzKbIVMUUN3ME25MlAzKG6PNITQVGFUSU6JRWK=
EFO-27NUDDZ4pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTlwMEWgcm0>MY\TRW5ITVJ?
CAPAN-1M4T4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\IeFEzUUN3ME25MlI{KG6PNVLYeHhvW0GQR1XS
DU-145NVrvT2k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTlwMkmgcm0>NF3aeWVUSU6JRWK=
A101DNGm4XZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITOU5lKSzVyPUmuN|chdk1?M2fTXXNCVkeHUh?=
ST486NILNTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DZdmlEPTB;OT60NUBvVQ>?NVrJVGhWW0GQR1XS
NCI-H1437MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4O3S2lEPTB;OT60NkBvVQ>?Mn32V2FPT0WU
HGC-27M1TrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3uwemlEPTB;OT62JI5OM{Sye3NCVkeHUh?=
8305CMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPWTWM2OD17Lk[0JI5OMnHjV2FPT0WU
OCUB-MNVm3[HF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fXemlEPTB;MUCuNFMhdk1?MorpV2FPT0WU
COLO-679MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmf5TWM2OD1zMD6wO{BvVQ>?MmrVV2FPT0WU
Detroit562MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXr6fZpjUUN3ME2xNE41OiCwTR?=NWXB[|NyW0GQR1XS
A204NEfhdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\qPHFPUUN3ME2xNU4yPiCwTR?=M{PXUXNCVkeHUh?=
NCI-H1734MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzsTWM2OD1zMT6yPUBvVQ>?Mn3HV2FPT0WU
MC-CARMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fEcGlEPTB;MUGuOVghdk1?NIrNW3lUSU6JRWK=
NCI-H2170MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXRSmpKSzVyPUGxMlk4KG6PMXPTRW5ITVJ?
NCI-SNU-5MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XLeWlEPTB;MUKuNVMhdk1?NGTPcIJUSU6JRWK=
HCE-TNXnUNYNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIOwPI5KSzVyPUGyMlQzKG6PM4HidXNCVkeHUh?=
KYSE-180Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTF{LkixJI5ONGjYeGxUSU6JRWK=
C8166NH\CcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\sc2lEPTB;MUOuNFghdk1?NGH5WFRUSU6JRWK=
NCI-H460MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2D6SmlEPTB;MUOuOVQhdk1?NF\W[ZhUSU6JRWK=
SNU-449NVezVHFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTF|Lke3JI5OMWDTRW5ITVJ?
MDA-MB-468NUjwSFB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTF2LkGyJI5ONIXhfXJUSU6JRWK=
COR-L23NFzpNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrq[XNKSzVyPUG0MlE{KG6PNIrKXGZUSU6JRWK=
CTV-1NFzXeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2H2[WlEPTB;MUSuNVQhdk1?NWXURXZ1W0GQR1XS
BL-41NFraVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7ZTWM2OD1zND6zO{BvVQ>?MojlV2FPT0WU
IGR-1MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXVOndKSzVyPUG0MlQzKG6PM{H4[HNCVkeHUh?=
TK10NGjydHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTF2LkS5JI5OM4jHWHNCVkeHUh?=
REHNWSz[pFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHnTWM2OD1zND61NUBvVQ>?NXHUcWlMW0GQR1XS
LU-139MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XYVWlEPTB;MUSuOVkhdk1?MUHTRW5ITVJ?
KP-N-YSM2fScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTF2Lkm3JI5OM4K2bXNCVkeHUh?=
PANC-10-05NIr2XHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnWXFBNUUN3ME2xOU4{QCCwTR?=MU\TRW5ITVJ?
HL-60M3K5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrqUmtMUUN3ME2xOU43QSCwTR?=MofCV2FPT0WU
T84NF3SOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LHcmlEPTB;MUWuPVYhdk1?MnPzV2FPT0WU
RPMI-8226NF3yO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUX5NYVvUUN3ME2xOk4xOiCwTR?=NFLRWY5USU6JRWK=
UM-UC-3MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;PNY06UUN3ME2xOk4yPiCwTR?=MlrGV2FPT0WU
TE-10MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rzfGlEPTB;MU[uNlEhdk1?M3O3c3NCVkeHUh?=
CAL-148MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HVdWlEPTB;MUeuNlMhdk1?NVexe2lsW0GQR1XS
BV-173NVLJWlRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlv1TWM2OD1zNz6yO{BvVQ>?MUfTRW5ITVJ?
Calu-3M1;VfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTF5LkK5JI5OMV3TRW5ITVJ?
RPMI-2650NGLxTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfWbJFKSzVyPUG3MlU6KG6PMmLMV2FPT0WU
MKN45NFjnUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTF5LkezJI5ONV[0VI1oW0GQR1XS
NUGC-3NEK3RmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrYOVdFUUN3ME2xPE4{PCCwTR?=MWfTRW5ITVJ?
NCI-H520Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYWwT4lzUUN3ME2xPE44PyCwTR?=NF\tdVNUSU6JRWK=
CCRF-CEMM{jZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTF6Lki1JI5ONVjaTZpPW0GQR1XS
NCI-H2405NIXxbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:1TWM2OD1zOT6xJI5OMUPTRW5ITVJ?
ES7MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLVTWM2OD1zOT63OkBvVQ>?MVXTRW5ITVJ?
BPH-1NYjwSIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPNOGh4UUN3ME2yNE4zQCCwTR?=NGXDNJlUSU6JRWK=
SASMoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnLfJFKSzVyPUKwMlUhdk1?MknlV2FPT0WU
HuCCT1M1rWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJyLkW4JI5ONYfIdXZUW0GQR1XS
LOUCYMlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJyLk[2JI5ONYr2ZWhMW0GQR1XS
NCI-H292M4m0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnO[4JKSzVyPUKwMlc6KG6PMlnBV2FPT0WU
G-361NHP1TFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoW2TWM2OD1{MT6wO{BvVQ>?M{LvNXNCVkeHUh?=
M059JNYDJRYtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTJzLkC4JI5OMkC2V2FPT0WU
NCI-H1651M2npTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrjTWM2OD1{MT6xNUBvVQ>?NWrLd2Z7W0GQR1XS
KALS-1NYXpZ49JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTJzLkO5JI5ONIXLSZNUSU6JRWK=
DJM-1NE\qSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PGZWlEPTB;MkGuOVkhdk1?NI\qenlUSU6JRWK=
AU565MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPXTWM2OD1{MT64N{BvVQ>?NFe4cmRUSU6JRWK=
HCC38M3H3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPXfFdKSzVyPUKxMlk2KG6PNFe1bGJUSU6JRWK=
U251NYPlcXJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTJ{LkK3JI5ONX\ZPXRiW0GQR1XS
ABC-1M2P5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrDTmJKSzVyPUKyMlY2KG6PNEftZlVUSU6JRWK=
SK-NEP-1NWe1OFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTJ{LkmzJI5ONGfmTVdUSU6JRWK=
CESSM3;a[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3SenhKSzVyPUKzMlE6KG6PNVnHO2NJW0GQR1XS
MIA-PaCa-2MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTCTWM2OD1{Mz6zOkBvVQ>?MXLTRW5ITVJ?
SUP-T1MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXFTWM2OD1{Mz60O{BvVQ>?M2jmeHNCVkeHUh?=
L-428Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7GcFhpUUN3ME2yN{43OiCwTR?=MVzTRW5ITVJ?
SW954MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;0bWlEPTB;MkOuOlghdk1?MonJV2FPT0WU
HO-1-N-1NF\HeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJ|Lke3JI5OMUPTRW5ITVJ?
CHP-126MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJ2LkG0JI5ONIPZRoVUSU6JRWK=
HMV-IINXzCOYdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIj6S2NKSzVyPUK0MlM1KG6PNW\vRYNGW0GQR1XS
NB10MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vlPGlEPTB;MkSuN|chdk1?Ml7pV2FPT0WU
A172NV35[5JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF2wUFBKSzVyPUK0MlcyKG6PMVvTRW5ITVJ?
MONO-MAC-6MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn[2TWM2OD1{ND64OEBvVQ>?MWXTRW5ITVJ?
NCI-H1650M{HPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofnTWM2OD1{NT60JI5OM4Ds[HNCVkeHUh?=
NH-12M1;lT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fpc2lEPTB;MkWuOUBvVQ>?Mk\hV2FPT0WU
ML-2NUWzS|FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIO0WFJKSzVyPUK1Mlc1KG6PMmqxV2FPT0WU
MZ2-MELMoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPJTWM2OD1{Nj6yNkBvVQ>?NHH6NY9USU6JRWK=
COLO-684NFy2e4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTJ4LkSxJI5OMkP1V2FPT0WU
HuP-T4NH7vVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXsTWM2OD1{Nz6zJI5OMo[3V2FPT0WU
SW837NILUZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjuVJBXUUN3ME2yO{43OiCwTR?=NXfIbmt6W0GQR1XS
MDA-MB-231NXr1TVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvrTWM2OD1{Nz63PEBvVQ>?M2j0VnNCVkeHUh?=
KYSE-140MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjCU3VKSzVyPUK3MlkyKG6PNIrsdIVUSU6JRWK=
NOMO-1NUXQc4VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\Cfo9KSzVyPUK4MlY5KG6PNXvKZoFwW0GQR1XS
GP5dMkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TBN2lEPTB;MkiuO|Ihdk1?MlLuV2FPT0WU
COR-L105M2HZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHHN|FTUUN3ME2yPU41OiCwTR?=NX:wUnNQW0GQR1XS
LS-411NNUD1NHk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3n2NWlEPTB;MkmuPFghdk1?MWHTRW5ITVJ?
NYNVTs[VR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzaTZF2UUN3ME2zNE4yQCCwTR?=NXjPRXRnW0GQR1XS
NCI-H2030MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTNyLkS1JI5ONF3o[ZZUSU6JRWK=
CCF-STTG1Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTNzLkSyJI5OMYjTRW5ITVJ?
NCI-H1703MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTNzLke4JI5ONUHMXIFNW0GQR1XS
TURMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfVTWM2OD1|Mj6wN{BvVQ>?MX3TRW5ITVJ?
NOS-1Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjwUmdKSzVyPUOyMlQ1KG6PM4Dad3NCVkeHUh?=
A2058MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILGUohKSzVyPUOyMlg{KG6PMYjTRW5ITVJ?
LCLC-103HMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTN|LkK1JI5ONHftU5ZUSU6JRWK=
NCI-H510ANFHVb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETNSY5KSzVyPUOzMlI4KG6PNH:5c3VUSU6JRWK=
BC-1M1HDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmC1TWM2OD1|Mz63O{BvVQ>?NXv0VXU6W0GQR1XS
SK-CO-1NVvo[VB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXjTWM2OD1|ND6wNUBvVQ>?M3HNXnNCVkeHUh?=
A673NE\qOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrBTWM2OD1|ND6xO{BvVQ>?NFvWTG5USU6JRWK=
VM-CUB-1NEDWfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGr2RWZKSzVyPUO0MlY6KG6PNGfRXGVUSU6JRWK=
HHM{n2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\4[WlEPTB;M{WuNFYhdk1?M2\zNnNCVkeHUh?=
CAL-27NXfR[GFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTrfWRUUUN3ME2zOU4yPiCwTR?=NFLhPW9USU6JRWK=
NEC8MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLOTWM2OD1|NT6zO{BvVQ>?MWTTRW5ITVJ?
BxPC-3MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXPWZBqUUN3ME2zOk46OSCwTR?=NFHo[WZUSU6JRWK=
SNB75MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NViwV|lNUUN3ME2zO{4zPCCwTR?=M37FRXNCVkeHUh?=
NB13NIrpOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\jTWM2OD1|OD6yN{BvVQ>?MU\TRW5ITVJ?
SK-OV-3NIXiellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTN6Lke0JI5OMkjtV2FPT0WU
ME-180NGXRc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLqTWM2OD1|OD64JI5ONVvDO3h{W0GQR1XS
JiyoyeP-2003MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHrVGxKSzVyPUO5MlM5KG6PNYDXNYhLW0GQR1XS
LU-134-ANEDKW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTRyLkCyJI5OMmmwV2FPT0WU
LS-123NXrQcGxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXyTWM2OD12MD6yPEBvVQ>?NE\WXVZUSU6JRWK=
COLO-800MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTRyLkW2JI5ONFTJ[YlUSU6JRWK=
LB831-BLCM2DmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHGwTnVKSzVyPUSxMlg2KG6PMmDaV2FPT0WU
NCI-H747NWrwUpl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTR{LkK4JI5OMVrTRW5ITVJ?
MZ7-melNGXUNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTR{Lk[2JI5ONHrFdIpUSU6JRWK=
GT3TKBNU[zfZo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWW4OHNvUUN3ME20Nk44OiCwTR?=NVviR2F4W0GQR1XS
MOLT-16NXnvdXNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXmxVXlNUUN3ME20N{4xPSCwTR?=MnPwV2FPT0WU
23132-87M2PGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2H1ZWlEPTB;NEOuNFUhdk1?MVPTRW5ITVJ?
PF-382MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nOOmlEPTB;NESuNlIhdk1?MlnBV2FPT0WU
ES3NVLFUIxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTR2Lk[gcm0>MV7TRW5ITVJ?
SW756NV\SWFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTR3LkG0JI5ONWH0dppCW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hertel LW, et al. Cancer Res, 1990, 50(14), 4417-4422.

[2] Bruns CJ, et al. Clin Cancer Res, 2000, 6(5), 1936-1948.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02538432 Not yet recruiting Prostate Cancer|Non-Small Cell Lung Cancer|Breast Cancer University of Maryland January 2017 Phase 2
NCT02767557 Not yet recruiting Unresectable Pancreatic Carcinoma Herlev Hospital|Celgene|Roche Pharma AG October 2016 Phase 2
NCT02806687 Not yet recruiting Pancreatic Adenocarcinoma University Hospital, Toulouse|BIOTHERAPY department of th  ...more University Hospital, Toulouse|BIOTHERAPY department of the clinical center of investigation- CIC 1436, Toulouse|InvivoGen Therapeutics October 2016 Phase 2
NCT02741388 Not yet recruiting B-cell Lymphoma The Lymphoma Academic Research Organisation|Karyopharm Th  ...more The Lymphoma Academic Research Organisation|Karyopharm Therapeutics, Inc September 2016 Phase 1
NCT02723838 Not yet recruiting Muscle-invasive Transitional Cell Carcinoma of the Bladder Oncolytics Biotech September 2016 Phase 1

view more

Chemical Information

Download Gemcitabine SDF
Molecular Weight (MW) 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LY-188011, NSC 613327
Solubility (25°C) * In vitro DMSO 15 mg/mL (56.99 mM)
Water 16 mg/mL warming (60.79 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo water 16mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2'-​deoxy-​2',​2'-​difluoro-cytidine

Customer Product Validation(3)


Click to enlarge
Rating
Source Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck
Method Xenograft Study
Cell Lines Athymic nude mice
Concentrations 120 mg/kg
Incubation Time 14 d
Results Gemcitabine treatment caused a threefold increase in stemness-high cell population.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck
Method Immunofluorescence
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 72 h
Results To finally investigate whether incorporation of drugs into RNA could be a general mechanism inducing SG assembly, we tested other chemotherapeutics known to incorporate into RNA, such as 5-azacytidine and 6-thioguanine, or as control, chemotherapeutics known to incorporate mainly into DNA, such as trifluorothymidine (TFT) or gemcitabine. HeLa cells treated with 5-azacytidine and 6-thioguanine displayed TIAR-positive foci, whereas HeLa cells treated with TFT or gemcitabine did exhibit such foci even with higher concentrations applied.

Click to enlarge
Rating
Source Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck
Method MTT assays
Cell Lines MCF7 cells, MCF10A cells
Concentrations 0.01-100 μM
Incubation Time 48 h
Results Gemcitabine potently inhibited the survival of MCF10A cells in a dose-dependent manner. The highest level of inhibition was observed with Gemcitabine HCl in concentration of 0.01 μM in MCF7 cells

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA/RNA Synthesis Products

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Recently Viewed Items

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us